Category Archives: Medicine Wellness Health

Medicine Wellness Health

biolitec®: Risk patients benefit from laser channel technology for BPH

Laser channel technology with biolitec® lasers successfully applied to treat in high-risk patients in Japan – Gentle, safe, fast, few side effects – Excellent hemostasis with fast, residue-free ablation

biolitec®: Risk patients benefit from laser channel technology for BPH

Prostate treatment with biolitec® fiber TWISTER (Source: biolitec biomedical technology GmbH)

Jena, July 11th, 2018 – The minimally invasive laser treatment LIFE (Laser Induced Flow Enhancement) by medical laser pioneer biolitec biomedical technology GmbH with its channel technology is particularly well suited for the treatment of benign prostate hyperplasia in high-risk patients. This is due to the optimal wavelength of the biolitec® laser (980 nm and 1470 nm) and to the special properties of the TWISTER and XCAVATOR® laser fibers, also specially developed by biolitec®. These are currently one of the gentlest, safest and fastest laser treatments with the fewest side effects and are therefore particularly suitable for high-risk patients. The channel technology offers the possibility of removing the tissue of the urinary tract of the prostate from the inside in a targeted manner without leaving any residue.

The biolitec® laser was one of the first lasers on the market with a wavelength of 980 nm and 1470 nm. This wavelength offers the highest absorption in water and hemoglobin and consequently enables excellent hemostasis. Less bleeding during the procedure improves visibility in the surgical area.
The TWISTER and XCAVATOR® laser fibers stand out due to their enlarged contact area and a special coating on the fiber tip, which enables faster ablation and more precise fiber guidance. The biolitec® fibers also work in contact mode. This significantly reduces the coagulation zone (smaller than 1 mm) and the bladder and surrounding tissue are protected, incontinence and sexual dysfunction are usually avoided.

The LIFE method has proven itself among other things in the treatment of high-risk patients. Urologists at Harasanshin Hospital Fukuoka in Japan have helped to develop this special channel technique and have operated on 26 patients who either suffer from diabetes and/or need to take anticoagulants. In addition, all patients had large prostates (on average over 100 to 200 g).

Doctors at Harasanshin Hospital Fukuoka were able to operate much faster than with conventional procedures – one hour on average – and to reach a large cavity without having to remove the tissue completely. The side effects, such as swelling, dysuria or retention, which are particularly common in large glands, did not occur. In addition, the treating physicians were enthusiastic about the good manageability and quality of the biolitec® laser system.

Further information on biolitec® lasers and special fibers as well as the possibilities of participating in workshops for doctors can be found on the website www.biolitec.com. Interested patients can find out more about doctors who use the LIFE method at www.info-prostate.com.

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

Best Hair Transplant in Turkey; Clinics and Offers

Best Hair Transplant in Turkey; Clinics and Offers

Over the last few years Turkey has became the first destination when it comes to health tourism. The best hair transplant in turkey offers all what a patient can ask for ; from the post surgery follow-up to the final guaranteed result. Hair transplant and plastic surgery are a flourishing filed in Turkey; clinics and hospitals are competing each other to offer the best services packages and to fulfill the needs and demands of their international patients , which qualifies them to be; not only the best hair transplant clinic in turkey but also in the world . If you are wondering how to find the best hair implants in turkey and how to make the best choice and choose the right clinic or surgeon this article is going to answer to the latter questions.

Best hair clinic in turkey is a little bit hard to find ; as we can’t name one clinic or hospital and refer to it as the ultimate best choice . Going through several clinics‘ and surgeons‘ results old patients‘ feedback and price offers can be the determinant point to either make a step forward and engage with the clinic or move on and look for the best hair transplant center in turkey . Sometimes it can be surprising when it comes to the difference in prices between clinics and hospitals ; for the reason of services including with the surgery and the used technique . Best hair transplant in turkey istanbul depends on the reputation of the surgeon; his experience and patients‘ satisfaction.

Best hair transplant in turkey istanbul offers a variety of methods ; Nowadays, hair transplantation can be reduced to two main techniques: FUE and DHI. Which method is best for me and how many grafts do i need ; is one session enough to cover all my baldness ; are the most frequently asked questions before engaging to have the surgery done , most of the time in the process of searching for the best place for hair transplant in turkey on the internet or online medical platforms can not answer to all your questions and inquires and even sometimes it can be misleading. For this reason, the best way to get an accurate estimate of the cost and best technique for you would be to set up a consultation with a hair transplant specialist ; best hair transplant doctors in turkey who can evaluate your particular situation. It is difficult to generalize an average cost of hair transplant procedures as it depends on the specificity of each patient’s hair loss circumstances.

Eurozen Hair exist a great team including 44 persons ,13 asistan nurses,12 persons who are experts at plastic surgeon and 19 experts proffessional hair planters.
We realize your hairtransplantation by expert surgens and team proffessional.Eurozen Hair Transplant is the company which has a legal accountability and is rigorous about the hospital and health personnel.
We serve for 16 years with our equipmant which has latest technology, equipped operating rooms,academic staff and special doctors in enviroment of hospital full-fledged.
Eurozen has mission and vision providing Turkey as one of the first places in the world about hair tranplantation, sharing many contents of information and technical, following the developments in Canada,U.S.A, and Europe about hair transplantation.

Company-Contact
EuroZen Hair Transplant Center
Ismail Zengin
Fulya Life Residence Merkez Mah. Prof. Dr. Bülent Tercan Sok. No:16 16
34394 istanbul
Phone: +90(542) 231 2810
E-Mail: info@eurozenhairtransplant.com
Url: https://en.eurozenhairtransplant.com

Press
EuroZen Hair Transplant Center
ahmet taş
Fulya Life Residence Merkez Mah. Prof. Dr. Bülent Tercan Sok. No:16 16
34394 istanbul
Phone: +90(542) 231 2810
E-Mail: info@eurozenhairtransplant.com
Url: https://en.eurozenhairtransplant.com

Medicine Wellness Health

healthbank enters into partnership with Sanovation

Health database platform healthbank gains over 200,000 additional users with pain diary apps from Sanovation

healthbank enters into partnership with Sanovation

Sanovation

Merger of two Swiss start-ups in the digital health sector. With the cooperation of the health data platforms healthbank from Baar and Sanovation AG from Zug, the users of the two innovative start-ups will receive a multitude of new possibilities with their health data.

Sanovation brings over 200,000 registered users of its pain diary apps „CatchMyPain“ and „Pain-Companion“ into the partnership. healthbank in return
offers users a highly secure storage for health data under their full control and an innovative data exchange platform. As a central agency for individuals, health service providers and researchers, healthbank increases the quality of care and lowers global health costs.

„The partnership with Sanovation is a further step towards a successful future for healthbank,“ explains Reto Schegg, CEO of healthbank. „With this partnership, users of the award-winning ‚CatchMyPain‘ and ‚Pain Companion‘ apps will be absolutely certain that their health data is not only safe and in full control. Users can also share data with recipients of their choice – participate in research projects worldwide and make their data available to research institutions. You will even be rewarded.“

One in five adults suffers from chronic pain
Today, according to Sanovation, one in five adults suffers from chronic pain. The aim of the intelli-gent pain diary „CatchMyPain“ is to enable a detailed, ongoing recording of pain samples. With „Pain Companion“, users can find similar patients by comparing the pain diaries, who can exchange information directly with each other or in a community. Thanks to the two Sanovation Apps, patients and their doctors and therapists receive a meaningful communication tool, especially through long-term recording.

The analysis of a large number of pain diaries, if users allow it, will lead to new findings in pain medicine. Reto Schegg adds: „The knowledge about chronic pain is currently scattered on many paper archives of doctors, therapists and hospitals. This makes it practically impossible to systematically compare and analyze pain cases. The cooperation between Sanovation and healthbank can signifi-cantly improve this problem. For Sanovation CEO and Chairman of the Board Roman Haag, this could improve the quality of life of millions of patients worldwide. In addition, administrative processes and treatments become more efficient and thus more cost-effective. „The cooperation with healthbank will improve the situation of chronic pain patients in the long term. On the other hand, we see great potential in the integration of additional data sources such as medication or fitness data, which is only made possible by the cooperation with healthbank. Haag explains. With the new basic data protection regulation of the European Union (GDPR), the cooperation makes an important contribution to the data protection of users. According to Reto Schegg, „CatchMyPain“ and „Pain Companion“ are just two of many applications that will be running on the healthbank platform in the future and with which users can manage their health data, explains Reto Schegg.

About Sanovation AG
The pain diary CatchMyPain is developed and maintained by the Swiss start-up Sanovation AG in Zug. Sanovation was founded in November 2011 and since then works exclusively on CatchMyPain. The idea for CatchMyPain came from the pain story of a co-founder. The application is primarily aimed at people with chronic pain who feel similar pain over a longer period of time. The vision of Sanovation AG is to help individual users on the basis of all collected user data by com-paring symptoms and making recommendations.

About healthbank
healthbank is the world’s first citizen-owned, neutral and independent health data transaction platform that enables peo-ple to share their data in a secure and privacy compliant way with other partners. healthbank connects data sources of all kinds from the entire health sector and rewards participants to share their health data for research purposes. Based in Switzerland, healthbank stands for Swiss neutrality, trust and data protection and enables participating citizens, research-ers and organisations with large amounts of data to network with each other. Thus, the value of health and medical data can be optimally tapped on this independent, global health platform. healthbank promotes innovations in health care, from prevention to cure, at a more reasonable price and of better quality, for the benefit of individuals and society.
www.healthbank.coop

Press contact healthbank

healthbank innovation AG
Karsten Stampa CFO/COO
Blegistrasse 17a, CH-6340 Baar
Tel. +41 (0) 41 552 24 00
press@healthbank.coop

Press contact Sanovation

Sanovation AG
Weinbergstrasse 48, CH-6300 Zug
Roman Haag, VRP
contact@sanovation.com

healthbank ist die weltweit erste bürgereigene, neutrale und unabhängige Gesundheitsdaten-Transaktionsplattform, die es Menschen ermöglicht ihre Daten auf sichere und datenschutzkonforme Art und Weise mit anderen Partnern zu teilen. healthbank verbindet Datenquellen aller Art aus dem gesamten Gesundheitsbereich und belohnt Teilnehmer, ihre Gesund-heitsdaten für Forschungszwecke zu teilen. Mit Sitz in der Schweiz steht healthbank für schweizerische Neutralität, Ver-trauen und Datenschutz und ermöglicht es den teilnehmenden Bürgern, Forschern und Organisationen mit großen Daten-mengen sich miteinander zu vernetzen. Damit kann der Wert von Gesundheits- und medizinischen Daten auf dieser unab-hängigen, globalen Gesundheitsplattform optimal erschlossen werden. healthbank fördert Innovationen im Gesundheits-wesen, von der Prävention bis zur Heilung, zu einem angemesseneren Preis und besserer Qualität – für das Wohl des Ein-zelnen und der Gesellschaft.
www.healthbank.coop

Company-Contact
healthbank
Pauline Geniets
Blegistrasse 17a
6340 Baar
Phone: +41 44 202 61 60
E-Mail: roger.huber@huber-media.ch
Url: http://www.healthbank.coop

Press
healthbank
Roger Huber
Gartenstrasse 36
8002 Zürich
Phone: +41 44 202 61 60
E-Mail: roger.huber@huber-media.ch
Url: http://www.healthbank.coop

Medicine Wellness Health

Maisense Presents Smart AI Cardiovascular Care Solution

Maisense Presents Smart AI Cardiovascular Care Solution

Freescan, the personal cardiovascular monitoring device (Source: © Maisense)

First all-in-1 Personal Cardiovascular Monitor and AI-based Stroke Prevention System to enable early detection of key factors indicating stroke risk

Hsinchu, Taiwan May 28th, 2018 – Maisense, an innovative startup, devotes itself to stroke prevention. The company“s corporate mission is to assist users with early detection of atrial fibrillation, and to support physicians in the efficient treatment and better cardiovascular care for their patients. Unlike other cardiovascular care products, which need multiple devices to measure ECG/EKG and blood pressure separately, Maisense Freescan in combination with the myFreescan App delivers an all-in-1 solution for early atrial fibrillation detection, arrhythmia (bradycardia and tachycardia) detection, pulse wave velocity, and blood pressure monitoring in a single device.

The Maisense Healthy Heart Hub (HHH) is a smart solution for cardiovascular care which consists of 3 components:

1. Freescan – the personal cardiovascular monitoring device for the patients and health conscious users. The device senses the lead 1 ECG and radial artery pulse by using 3 electrodes (1 as RA, 1 as LA, 1 as RL) combined with 1 pressure sensor. With the aforementioned bio-signals, Freescan can register parameters such as pulse transmission time (PTT), and calculates systole (SYS) and diastole (DIA) blood pressure respectively according to a formula. The devices can also calculate the heart rate (HR) and indicates irregular heartbeat. With its build-in Bluetooth technology, Freescan uploads each measurement to the Mobile App, and combines it with Maisense artificial intelligence (AI) to provide additional conclusions. The device has received an EU CE medical certification.

2. myFreescan – the Mobile App for patients or health conscious users to keep track of their personal health trends and to screen AFib/Arrhythmia. In addition, the pulse waveform and ECG/EKG waveform captured by Freescan provide the artery pulse wave velocity which is the indicator for artery stiffness and alerts the user to seek professional medical advice.

3. The Patient Care System – the platform used by doctors and professional physicians to monitor a patient“s vital parameters. Through the system personalized advices can be given instantly to guide patients. A detailed health report can be generated by the doctors via the system to support the patients for short-term/long-term heart health monitoring.
Freescan could proof a highly exact performance compared with Holter monitor systems in clinical field tests. In May 2018, Maisense finished the clinical research on AFib detection in the Chang-Gung Memorial Hospital, Keelung, Taiwan. The clinical results demonstrate the feasibility of using Freescan in detecting AFib as the preliminary screening results with over 95% sensitivity and over 99% specificity. The clinical results are under submission to the American Heart Association (AHA) 2018.

Maisense will present the solution at the ESH (European Society of Hypertension) conference in Barcelona from June 8th-11th in hall 8, booth 22, In addition to product demos for Freescan, myFreescan and the Patient Care System, the Maisense experts are available to discuss atrial fibrillation detection and the latest results of clinical studies.

Freescan is now available in Germany at Mindtech ( https://www.mindtecstore.com/Maisense_1). Maisense is looking for distributors in European Union.

Maisense is proud to be a member of the Global Research & Industry Alliance (GLORIA-Semicon) which focuses on future-oriented technology and builds a cooperation platform between universities and the industry. The organization stimulates innovation and introduces Taiwan startup companies to the global market. GLORIA will also exhibit alongside Maisense at ESH – booth 22.

About Maisense:
Maisense is an innovative startup working in non-invasive medical cardiovascular monitoring for personal use, combined with artificial intelligence software for stroke prevention including AFib/arrhythmia/artery stiffness detection for professional physician use. Founded in 2012, Maisense was granted the award for „Best Investment Potential“ by Taiwan“s Ministry of Economic Affairs. Maisense“s Freescan is the world first cuffless blood pressure monitor measuring directly from wrist pulse and it has received EU CE medical certification. It has been honored with the 2015 National Innovation Award in Taiwan, as well as ranking second among the Top 10 Innovative Health Products at the Arab Health 2016 fair in Dubai. In 2017, it has received the „Taiwan top 10 coolest innovative startups award“ from the Ministry of Science and Tech in Taiwan. For more information, visit www.maisense.com

About GLORIA-Semicon:
„GLORIA-Semicon“ – (Global Research & Industry Alliance Semiconductor) of Taiwan Ministry of Science & Technology is a platform that promotes high value-added and cross-field innovative products and services, and also dedicates in exploring and expanding the opportunities for members“ pioneering design to connect with Taiwan industry and academy resources. For more information, please visit http://riact.nctu.edu.tw/

GLORIA-Semicon is now coordinating a special interest group (SIG) for biomedical devices providers. Connections in between medical doctors, clinical trials as well as interdisciplinary researches are being sponsored by Taiwan government. We welcome international partners and jointly explore new businesses and channels especially in Chinese communities.

Dedication of GLORIA-Semicon:
– Allying global entrepreneurs with Taiwan semiconductor eco-system
– Providing one-stop services
– Facilitating global entrepreneurs in Taiwan to connect with local resources
– Collaborating with excellent academic groups in technical development

Company-Contact
Pressoffice Maisense
Wibke Sonderkamp
Münchner Str. 14
85748 Garching bei München
Phone: +49.89.360363.40
E-Mail: wibke@gcpr.net
Url: http://www.maisense.com/en/

Press
Pressoffice Maisense
Laura Lehmann
Münchner Str. 14
85748 Garching bei München
Phone: +49.89.360363.52
E-Mail: laura@gcpr.net
Url: https://www.gcpr.de/

Medicine Wellness Health

www.biolitec.com: New website presents modern medical laser therapies

biolitec® has launched a new website – Functional modern design – Worldwide leading developer and manufacturer of minimally invasive laser therapies – Successful research and development in areas such as phlebology and proctology – 10 years ELVeS®

www.biolitec.com: New website presents modern medical laser therapies

biolitec®_Homepage_en (Source: @biolitec biomedical technology gmbh)

Jena, May 22, 2018 – The developer and manufacturer of medical laser systems for minimally-invasive therapies, biolitec biomedical technology GmbH, has unveiled its new online presence. A modern layout now stands for an adapted innovative website functionality and a better overview of the company’s versatile product and application areas: Thanks to the new tile design, the entire website is structured in a way that the extensive range of medical applications and laser systems of biolitec® can be recognized at first glance.

This principle of fast recognition can be found both in the subject area for doctors and for patients. This, for instance, gives doctors an immediate overview of all biolitec® lasers. For example, if the visitor clicks on the „Dual 100“ tile, he can, due to the simple depiction, see all the therapeutic areas in which this laser can be used.

The same applies to patients: The respective therapy subpages under the menu item „patients“ lead directly to the patient websites adapted to the special needs of patients, such as www.info-varicose-vein.com, which can also be accessed as independent websites.

Founded more than 30 years ago, biolitec® has become one of the world’s leading companies in the field of minimally invasive laser therapies – due to continuous research and development of its products. Thanks to subsidiaries, including in South America and Asia, its innovative laser systems and methods are available for a wide range of applications for gentle and low-intensity treatment options all around the globe. biolitec® lasers are often innovative alternatives to conventional treatment methods in phlebology, proctology, thoracic surgery, urology, gynecology, ENT and orthopedics.

For 10 years now, the unique ELVeS® Radial® 2-ring laser fiber of biolitec®, with its efficient and simple technology, has been convincing in the treatment of varicose veins.

As a result of intensive research, biolitec® has always been able to offer the most modern possibilities in minimally invasive laser medicine. The new LEONARDO® laser family by biolitec® includes the only laser systems available on the market in which two wavelengths can be adjusted and used independently and continuously during the treatment. The universal applicability of the lasers in various fields of application is unique.

Further information on all products and applications of the laser therapies by biolitec® is available directly on the new website www.biolitec.com.

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

First patient treated in First-in-Man study of CoreMedic“s ChordArt™ mitral valve repair system

16 May 2018. Privately-held CoreMedic announces the start of a first-in-man „Chagall“ study to evaluate new minimally-invasive valve repair technology.

CoreMedic is developing ChordArt, a novel transfemoral chordal repair system to address unmet needs in the treatment of degenerative heart disease with mitral valve insufficiency, the most common valve pathology affecting more than 7 million patients worldwide. The ChordArt implant is used to replace the ruptured or elongated chordae of the valve and re-establishes the connection of the valve leaflets with the papillary muscle to restore the proper function. As ChordArt reduces the complexity of the procedure, both patients and physicians will benefit.

The „Chagall“ Trial is a prospective, multicenter, first-in-man study intended to establish the safety and effectiveness of the ChordArt System. The study was approved to enroll up to 40 subjects at up to 6 European centers. This study is the first trial of its kind to treat patients that have ruptured or elongated mi-tral chords with the ChordArt System.

The first-in-man (FIM) case using ChordArt was treated by the Heart Team led by Prof. Kstutis Ručinskas at the Vilnius Uni-versity Hospital, Lithuania. The ChordArt treatment was aimed at improving procedural outcomes and allowing standardized placement of the artificial chords with a dedicated, reproducible technique.

The patient recovered very well from the intervention and is continuously doing well. A 30 day follow-up showed no complications.

„Using the ChordArt reduced the invasiveness and duration of the procedure by repairing the valve in a fast, precise and safe way. This allowed the Heart Team to focus on the procedure and timing rather than manually placing the artificial chords to resolve the mitral insufficiency“ said Dr. Alberto Weber, Her-zzentrum Hirslanden, Zurich, Switzerland, who proctored the procedure. „Thanks to the ease of the ChordArt deployment technique, this was the fastest mitral valve chordal repair I have ever witnessed.“

For Thomas Bauer, CEO of CoreMedic, „The first clinical use of ChordArt is a major milestone in our path towards developing the best in class transfemoral mitral valve chordal repair system“. Hubertus Leonhardt, Managing Partner of medical device investor SHS, commented: „In 2017 we invested in CoreMedic to advance the development of ChordArt. We look forward to the results of clinical trials that will validate the applications of this breakthrough device.“

About Mitral Regurgitation:
Mitral valve regurgitation (MR) is a condition in which the mitral valve leaflets fail to close properly, allowing significant backflow of blood from the left ventricle into the left atrium during systole. Valve disease prevalence rises dramatically with age, reaching epidemic levels in the elderly.
MR is the most common valve pathology in the US. Over 7 million people suffer from the disease and each year 250,000 patients are diagnosed with MR. If untreated, MR can cause shortness of breath, decreased cardiac output, intolerance to physical exercise, congestive heart failure and death.
The standard-of-care in surgically treating degenerative MR involves replacing ruptured or elongated valve chordae with artificial implants to restore the function of the valve.
Implanting the standard artificial chordae requires complex and long procedural steps. This complexity is associated with risks including failure of the valve repair or the need to repeat the operation, the use of a cardiac bypass machine and stopping the heart.

About CoreMedic:
CoreMedic is dedicated to develop devices and therapies to dramatically improve the quality of life of patients with heart valve diseases, a primary challenge in global healthcare.
CoreMedic“s flagship product ChordArt is a transfemoral system for mitral valve chordal repair in the beating heart. ChordArt™ offers a first line therapy option for patients with mitral valve dysfunction and represents a less invasive procedure compared to the current surgical methods with open-chest or trans-apical access. ChordArt is designed to allow mitral repair in a wider patient population. ChordArt™ is currently under clinical evaluation in European clinics.
CoreMedic is a privately held medical device company headquartered in Radolfzell, Germany with a subsidiary in Biel/Bienne, Switzerland. CoreMedic is EN ISO 13485 certified.
The investor base consists of founders, private investors and medical device investor SHS Gesellschaft für Beteiligungsmanagement mbH ( www.shs-capital.eu).
For further information, please visit www.coremedic.ch

Company-Contact
CoreMedic GmbH
Thomas Bauer
Bismarckstrasse 12
72072 Tübingen
Phone: 089 20003038
E-Mail: info@coremedic.ch
Url: http://www.coremedic.ch

Press
IWK GmbH
Dr. Reinhard Saller
Ohmstr. 1
80802 München
Phone: 089 20003038
E-Mail: reinhard.saller@iwk-cp.com
Url: http://www.iwk-cp.com

Medicine Wellness Health

Alzheimer’s disease: Patients benefit from nuclear imaging

(Vienna, 19 April 2018) With the help of Positron emission tomography (PET) Alzheimer“s disease (AD) can be detected long before the onset of the symptoms by making beta-amyloid in the brain visible. However, since there is still no cure for AD the question has been raised if such a diagnosis is really beneficial for the patient or rather more of a burden. First results of a large study, currently under way, show that PET diagnosis helped to improve medical management and counseling in over 65% of the patients. „AD patients clearly benefit from nuclear imaging,“ says Dr. Valentina Garibotto, expert of the European Association of Nuclear Medicine (EANM).

Alzheimer“s disease is the most frequent cause of dementia and one of the most important causes of disability in the elderly. The condition induces a decline in mental ability that usually develops and progresses slowly. Memory and judgment are impaired, and personality may deteriorate. The target of the PET examination is beta-amyloid, which is the chief component of plaques that are one of the hallmarks of Alzheimer“s. Recently developed tracers (radioactively labelled substances the patient is injected with) make these plaques visible on the computer screen. By applying this method the likelihood of Alzheimer“s disease can be established in patients with a higher degree of certainty, as compared with other routine diagnostic tools.

PET exams improve health care management
While its accuracy is uncontroversial the benefit of nuclear imaging for AD patients has frequently been questioned: Since there is no cure for this disease the gained diagnostic knowledge might be considered not only useless but an unnecessary psychological burden for the patient while he is still fit. In order to clarify this matter and to examine the actual impact of PET procedures on AD patient care and health outcome two large studies are currently under way: The IDEAS study (Imaging Dementia-Evidence for Amyloid Scanning) in the USA (www.ideas-study.org) and the AMYPAD study (Amyloid Imaging to prevent AD) in Europe (amypad.eu).

IDEAS started in 2016 and includes 18.000 participants. First results show that the outcome of PET scans have concrete beneficial consequences: They led to a change in medical and general health care management in around 65% of the patients. These changes consisted among other things in different drug prescriptions, making use of the fact that amyloid imaging allows doctors to determine with high accuracy whether in patients with mild symptoms Alzheimer“s is the cause or whether it can be excluded, so that some other kind of dementia or another condition has to be taken into account. Thus, depending on the PET exam results doctors changed to drugs specific for Alzheimer (namely aceltycholinesterase inhibitors) or they reversely abandoned these drugs in favor of a better suited medication, for exampleantidepressants or antipsychotics. PET scan results in favor of AD also induced an appropriate counseling about safety and future planning, thus helping patients and their friends and family to avoid preventable risks. For example, a diabetic who is also diagnosed with AD would not be left alone any longer to manage his insuline doses. „These interim results already provide convincing evidence that AD patients benefit largely from a more accurate diagnosis and we expect further study outcomes to complete the picture,“ says Dr. Valentina Garibotto of the EANM Neuroimaging Committee.

Nuclear imaging pivotal in AD research
Further important insights are to be expected of the AMYPAD study which has just started. This is a collaborative research initiative and part of the European Innovative Medicines Initiative (IMI). The overall goal of the program is to determine the value of amyloid PET imaging to diagnose and guide treatment, namely clinical trials, in AD. „Despite the hitherto unsatisfying results of therapeutic trials, our knowledge and understanding of AD has dramatically evolved over the last decades and PET imaging has played and still plays an increasingly central role. Accordingly, the next EANM focus meeting will be fully dedicated to the field of neuroimaging in AD. Entitled „Molecular Imaging of Dementia – The future is here“ it will invite worldwide experts to update the community on the latest developments,“says Dr. Garibotto.

www.whatisnuclearmedicine.com
www.eanm.org

Presseagentur für Medizinthemen

Contact
impressum health & science communication
Frank von Spee
Hohe Brücke 1
20459 Hamburg
Phone: 040 31786410
E-Mail: vonspee@impressum.de
Url: http://www.impressum.de

Medicine Wellness Health

LEONARDO® DUAL by biolitec®: First medical laser for multifunctional applications in minimally invasive therapies

LEONARDO® laser family first universally applicable medical laser system with a combination of two wavelengths for use in several disciplines

LEONARDO® DUAL by biolitec®: First medical laser for multifunctional applications in minimally invasive therapies

biolitec® LEONARDO® DUAL lasers family (Source: biolitec biomedical technology GmbH)

Jena, April 19th, 2018 – The unique medical laser system LEONARDO® DUAL consists of lasers with 45 watt, 100 watt and 200 watt power ranges. These lasers are the most versatile medical lasers available for medical la-ser treatments, offering a variety of tissue interactions – for open and for endoscopic procedures with contact or non-contact delivery options. The possibility to use two wavelengths in one compact, mobile and space-saving laser system constitutes a clear benefit for the user, just as the multidisciplinary use of the lasers and the low-maintenance. Each wavelength can be individually selected or blended together to offer the desired tissue effects, such as incision, excision, vaporization, hemostasis and coagulation of soft tissue. All of the lasers are equipped with the two wavelengths of 980 nm and 1470 nm, which can be continuously used during the treatment.

The new LEONARDO® DUAL series lasers are suitable for minimally invasive procedures in phlebology, proctology, urology, gynecology, orthopedics, thoracic surgery, pneumology, ENT and aesthetic surgery. As the lasers feature not only a wavelength of 980 nm but also of 1470 nm, they are also ideally suited for the use in phlebology. The laser procedure with a wavelength of 1470 nm minimizes any post-operative inflammatory pain and bruising, due to a 400 times greater absorption coefficient in water compared to 810 nm lasers targeting hemoglobin. In addition, an easy-to-use system for a significantly improved treatment outcome is provided by means of the radial (360°) emission of the patented ELVeS® Radial® 2ring fiber.

The ELVeS® Radial® 2ring fiber splits the energy in two phases, which leads to an effective closure of the vein. By avoiding perforation of the vein wall and associated thermal irritation of the surrounding tissue, post-operative pain is minimized. The ELVeS® Radial® 2ring slim fiber was especially designed for the treatment of superficial venous reflux on perforator veins and small saphenous veins.

With the biolitec® therapies FiLaC® (Fistula-tract Laser Closure for anal fistulae), SiLaC (Sinus Pilonidalis treatment) and LHP® (LaserHemorrhoidoPlasty for hemorrhoids) for proctology, biolitec® introduced a new innovative minimally invasive method, where the diseased tissue is irradiated from the inside with the laser energy and thus gently destroyed.

Also part of the family and suitable for varicose vein treatment is the LEONARDO® Mini 1470 nm. Weighing only 900 grams, this device can be used mobile in the established treatment methods of biolitec® for venous diseases and other medical treatments. Besides the lasers, biolitec® provides a wide range of accessories and offers suitable fibers with specific characteristics that are perfectly coordinated with versatile therapeutic areas and the respective application, due to continuous research and development.

If you are interested in presentations or congresses on the subject of minimally invasive medical laser therapies by biolitec®, please have a look at our website www.biolitec.com (section Company/Events).

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

Global Dosing Systems Market Status and Prospect, Forecast 2018 to 2026

Global Dosing Systems Market Status and Prospect, Forecast 2018 to 2026

Dosing systems are commonly used to inject fluids or chemicals in large or small quantity in production & processing, and is used in various processing and manufacturing industries such as textile, thermal power stations, oil & gas, water treatment, food & beverages, pharmaceuticals, paper & pulp, chemical processes, etc. Dosing systems are designed with high accuracy, and it ensures high safety, and security measures, longer service life, and excellent performance.

Increasing importance of wastewater treatment by national governments, and increase in production rate of pharmaceuticals and chemical processing industries are key factors driving growth of the global dosing systems market over the forecast period. In addition, increasing preference for dosing systems, owing to factors such as faster outputs, impart precision, and effectiveness are expected to fuels growth of the global dosing systems market. Moreover, increasing consumer awareness, and technological advancement with chemical processing industries are expected to further fuel growth of the global dosing systems market over the forecast period.

However, high cost of raw materials, and increasing number of coal bed methane reserves are key factors restraining growth of the global dosing systems market over the forecast period. In addition, issues related to lack of greenfield investments is another factor expected to hamper growth of the global dosing systems market in the near future.

Moreover, increasing trend towards automation, innovation, and increasing number of software in these systems are expected to spur demand for dosing systems during the forecast period.

Do Inquiry of the Report Here: https://marketresearch.biz/report/dosing-systems-market/#inquiry

The market in North America dominates the global dosing systems market in terms of revenue, owing to rapidly growing industrial sectors, followed by Europe respectively. The market in Asia Pacific is expected to witness highest growth in terms of revenue during the forecast period owing to presence of manufacturing facilities of large chemical, food & beverages, paper & pulp, and pharmaceutical companies in countries in this region.

Key players in the global dosing systems market include GRUNDFOS GMBH, IDEX Corporation, ProMinent GmbH, Seko S.p.A., EMEC S.r.l., Gee & Company (Effluent Control & Recovery) Limited, LEWA GmbH, and NETZSCH Pumpen & Systeme GmbH, Blue-White Industries, Ltd., and SPX Corporation.

Prudour Pvt. Ltd. ( https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions.

Contact
MarketResearch.Biz
Krutika Bhoot
Prudour Pvt. Ltd. 420 Lexington Avenue, Suite 300 NY
10170 New York City
Phone: +1 347 826 1876
E-Mail: krutika@marketresearch.biz
Url: https://marketresearch.biz/

Medicine Wellness Health

Global Infection Control Market Status and Prospect, Forecast 2018 to 2026

Global Infection Control Market Status and Prospect, Forecast 2018 to 2026

Infection control is concerned with preventing health care associated infection and aseptic technique is a major component of all invasive surgical process. Infection prevention and control plays crucial role in hospital and clinics, as it prevents the spread of infections in healthcare settings. According to World Health Organization data, 1 in 10 patients get an infection while receiving care. Furthermore, preventing infection control can reduce 30% of health care-associated infections. Hospital acquired infection is most common in intensive care unit and are significantly associated with increased morbidity and mortality. Moreover, infection control affects patient recovery.

Increasing incidence of hospital acquired infection is expected to drive the growth of infection control market. Moreover, rising awareness about several infections and increased hospital admission, owing to the rapidly growing geriatric population are other factors anticipated to further drive growth of the global infection control market over the forecast period. In addition, increasing demand for non-disposable surgical equipment in hospitals/clinics and increasing number of surgical procedure is anticipated to future drive the growth of the global infection control market over the forecast period.

Technological advancement and drug innovation resulting in minimal hospital stay is major factor restraining growth of the global infection control market.

The global infection control market report has been segmented on the basis of type, application, and region. On the basis of region, the global infection control market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Do Inquiry of the Report Here: https://marketresearch.biz/report/infection-control-market/#inquiry

North America market dominates the global infection control market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to well-developed healthcare infrastructure and availability of skilled medical personnel, rising regulatory concerns and government initiatives in the region. Europe accounts for second-largest revenue share contribution to the global infection control market, followed by markets in Latin America, Asia Pacific, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to the growing demand for infection control products and services and increasing number of surgical procedures in the region.

Some prominent players in the global infection control market are 3M Company, MMM Group, Metrex Research, LLC., Cantel Medical Corporation, Belimed AG, STERUS Corporation, Getinge Group, Halyard Health, and Pal International

Prudour Pvt. Ltd. ( https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions.

Contact
MarketResearch.Biz
Krutika Bhoot
Prudour Pvt. Ltd. 420 Lexington Avenue, Suite 300 NY
10170 New York City
Phone: +1 347 826 1876
E-Mail: krutika@marketresearch.biz
Url: https://marketresearch.biz/